Anti-Human CD30 Recombinant Antibody (Iratumumab) (CAT#: TAB-144)

Tosetti, Francesca, et al. "Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells." Oncoimmunology 7.5 (2018): e1421889. https://doi.org/10.1080/2162402x.2017.1421889

This study investigates the role of ADAM10 (A Disintegrin And Metalloprotease 10) inhibitors in preventing sheddase activity in Hodgkin lymphoma (HL) and stromal cells. The research demonstrates that the mature bioactive form of ADAM10 is released in exosome-like vesicles (ExoV) by both HL cells and lymph node mesenchymal stromal cells. Notably, the researchers found that specific ADAM10 inhibitors (LT4 and CAM29) can localize in the endolysosomal compartment, be released in ExoV, and subsequently be endocytosed by bystander cells. These inhibitors effectively prevent ADAM10 sheddase activity carried by ExoV, which otherwise facilitates the release of cytokines like TNFα (a lymphoma growth factor) and soluble molecules such as sMICA or sCD30 that potentially interfere with host immune surveillance or immunotherapy.
Creative Biolabs provided the anti-CD30 human antibody Iratumumab for this research, which was essential for studying antibody-dependent cellular cytotoxicity (ADCC) against HL cells. The antibody enabled researchers to demonstrate that ADAM10 inhibitors can reduce CD30 shedding and maintain the biological effects of both the antibody-drug conjugate Brentuximab-Vedotin and Iratumumab on HL cells. This contribution was significant as it helped establish that ADAM10 blockers can interfere with the immune escape process in the lymphoma microenvironment, potentially allowing for the development of effective anti-lymphoma immune responses and efficient antibody-based immunotherapies.